Skip to content

Safety and utility of endoscopic balloon dilation in small intestinal strictures of Crohn's disease

Safety and utility of endoscopic balloon dilation in small intestinal strictures of Crohn's disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1030220093
Enrollment
40
Registered
2022-05-28
Start date
2022-05-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's disease Crohn's disease, small intestinal stricture, endoscopic balloon dilation

Interventions

None listed

Sponsors

Yano Tomonori
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: -Cases with endoscopic balloon dilation planned for Crohn's disease patients with small intestinal strictures who have been hospitalized or visited from the date of approval completion to December 31, 2024, in the department of Gastroenterology, Jichi Medical University Hospital. -Regardless of gender or nationality

Exclusion criteria

Exclusion criteria: -Cases that refused to participate in this study -Cases in which the information in the medical records (age at the time of diagnosis, treatment details, etc.) is inadequate. -Patients with only anastomotic stricture -Cases with long stricture of 5 cm or more, fistula, fissure, abscess, deep ulcer, high degree of adhesion, flexion, and high risk of bleeding and perforation associated with the procedure, which are contraindicated for endoscopic balloon dilation, -Cases that the principal investigator deems inappropriate as a research subject

Design outcomes

Primary

MeasureTime frame
Improvement of stricture inner diameter during follow-up after balloon dilation

Secondary

MeasureTime frame
Adverse events associated with balloon dilation, avoidance rate of re-balloon dilation, avoidance rate of surgical treatment, improvement rate of stricture symptoms, QOL questionnaire for inflammatory bowel disease (SIBDQ), Leucine-rich alpha 2 glycoprotein (LRG), fecal calprotectin

Contacts

Public ContactJun Owada

Jichi Medical University

r1507oj@jichi.ac.jp+81-285-58-7348

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026